Myocarditis Reported After BNT162b2 Vaccination in Israel
Estimated incidence highest among males 16 to 29 years; second study shows highest standardized incidence ratio for males 16 to 19 years
Estimated incidence highest among males 16 to 29 years; second study shows highest standardized incidence ratio for males 16 to 19 years
Incidence of myocarditis 5.8 cases per 1 million adults after the second dose; safety signal for increased myocarditis seen in young men
However, the long-term effects of myocarditis in children associated with COVID-19 vaccination are unknown
Vaccination not associated with elevated risk for most of the adverse events examined; association found with increased risk for myocarditis, but risk higher in association with SARS-CoV-2 infection
However, health officials emphasize that COVID-19 puts someone at much greater risk for heart inflammation than getting the vaccine does